About Dicerna Pharmaceuticals
Dicerna Pharmaceuticals is a Healthcare company based in Lexington (United States) founded in 2007, and was acquired by Novo Nordisk in November 2021. Drugs are developed using RNA interference technology platform. It operates in the Healthcare and Technology sectors. Dicerna Pharmaceuticals has raised $106.45 million across 7 funding rounds from investors including Lilly, Novo Nordisk and RA Capital. The company has 337 employees. Dicerna Pharmaceuticals offers products and services including Wegovy and Ozempic. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its legal entity is DICERNA PHARMACEUTICALS INC. Its competitors include Alnylam, Denali Therapeutics and Avidity Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2007, Dicerna Pharmaceuticals is based in Lexington, United States, within the biotechnology sector. Therapeutics are developed through RNA interference technology for various conditions. A lead RNA product targets hepatocellular carcinoma, while other candidates address primary hyperoxaluria, genetic liver diseases, cardiovascular issues, and hepatitis B virus. The GalXC platform is applied to silence genes associated with these diseases.
- Headquarters Lexington, United States
- Employees 337
- Stage Acquired
- SectorsHealthcareTechnology
- Email••••••••
- Phone•••• ••••
- Website dicerna.com
- Social LinkedIn X Facebook
- Acquired by Novo Nordisk (Nov 2021)
- Legal Name Dicerna Pharmaceuticals Inc
- Annual Revenue$164.31 M (USD)587as on Dec 31, 2020
- Net Profit-$112.75 M (USD)6as on Dec 31, 2020
- EBITDA-$113.21 M (USD)12as on Dec 31, 2020
- Total Equity Funding$106.45M (USD)
in 7 rounds
- Latest Funding Round$100M (USD), Post-IPO
Dec 2018
- InvestorsLilly
& 16 more
- Employee Count337
- Acquired byNovo Nordisk
(Nov 2021)
Products & Services of Dicerna Pharmaceuticals
Dicerna Pharmaceuticals offers a comprehensive portfolio of products and services, including Wegovy and Ozempic.
Medication for weight management in adults with obesity.
Drug for managing type 2 diabetes and related conditions.
Funding Insights of Dicerna Pharmaceuticals
Dicerna Pharmaceuticals has successfully raised a total of $106.45M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $100 million completed in December 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $106.45M
- Total Rounds 7
- Last Round Post-IPO — $100M
- First Round $8.4M
(Jul 2008)
- Investors Count 16
All 7 funding rounds of Dicerna Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2018 | $100M | Post-IPO | – | – | |
| Mar 2017 | $70M | Post-IPO | – | – | |
| Aug 2013 | $60M | Series C | – | RA Capital Management | |
| Oct 2010 | $4M | Series B | – | – | |
| Oct 2010 | $29.05M | Series B | – | Domain Associates | |
| Jun 2010 | $5M | Series A | – | – | – |
| Jul 2008 | $8.4M | Series A | – | – |
17 investors in total: 17 institutional.
Investors in Dicerna Pharmaceuticals
Dicerna Pharmaceuticals has secured backing from 17 investors, including institutional and venture fund investors. Prominent investors backing the company include Lilly, Novo Nordisk and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
US life sciences companies are invested in by Skyline Ventures. | skylineventures.com | Palo Alto, United States | ||
Investments are focused on pharmaceutical, biotechnology, and medical sectors. | baincapitallifesciences.com | Boston, United States | ||
Healthcare startups are funded by this venture capital firm. | Ponte Vedra, United States | |||
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
Early stage VC firm investing in the US and Korea | oxbio.com | Boston, United States | ||
A biotechnology venture capital firm investing in innovative science. | srone.com | |||
Venture capital firm focused on multiple sectors | brooksidecapital.com | San Francisco, United States | ||
Private investment firm managing assets and expanding into equity, credit, and real estate services. | 1984 | baincapitalprivateequity.com | London, United Kingdom | |
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States |
Investor details for Dicerna Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Dicerna Pharmaceuticals
1136 people are tracked at Dicerna Pharmaceuticals (545 in leadership, 9 in board & advisors, 582 in team); the tracked headcount is 337.
| Name | Role | Group |
|---|---|---|
Anne-Kristine Prag Steinitz | Corporate Vice President Strategic Scientific Communication, Global Medical Affairs | Leadership |
Cecilie Heerdegen Jepsen | Head Of Translational Medicine | Leadership |
Malgorzata Wnuk | Strategic Finance & Project Director | Leadership |
Allegra Kaufman | Executive Director, Clinical Development Strategy | Leadership |
Greg Horikoshi | Associate Director Commercial Execution | Leadership |
Claudia Laven | Vice President | Obesity Care | Leadership |
David Scott | Director, Legal, Ethics, Compliance And Quality | Leadership |
Sofie Inari Castella | Global Director, Scientific Publications | Leadership |
Rasmus Sonne Henniker Heaton | Sr. Business & Project Partner | Leadership |
Ghita Bahbouhi | Supply Chain Analytics Partner | Leadership |
Teresa Sophie K. | Director, IME & Medical Association Partnerships | Leadership |
Ulrik Ullum | Senior Director | Leadership |
Katy Long | Snr Dir, HR Business Partner, International Operations | Leadership |
Victor Vazquez | Talent Acquisition Partner Americas (latam, USA & Canada) | Leadership |
Al Willis | Senior Director - Deployment Strategy & Sales Innovation | Leadership |
Morten Engelund | Corporate Vice President, Total Rewards And Mobility | Leadership |
Briana Dunn | Associate Director Search And Evaluation | Leadership |
Jacob Sten Petersen | Corporate Vice President, Stem Cell R&D | Leadership |
Konstantinos Ratsikas | Senior Supply Chain Partner | Leadership |
Pratik Dherange | Associate Director, Regulatory Affairs Strategy | Leadership |
1116 more people are available in the full profile.
Complete people profiles for Dicerna Pharmaceuticals
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Dicerna Pharmaceuticals
5 dated milestones of Dicerna Pharmaceuticals across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Dicerna Pharmaceuticals is founded.
- Funding First funding round of $8.4M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $100.0M.
- Exit Acquired by Novo Nordisk.
Competitors of Dicerna Pharmaceuticals
Dicerna Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Alnylam, Denali Therapeutics and Avidity Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. |
Detailed competitors of Dicerna Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Dicerna Pharmaceuticals
Websites that share an audience with Dicerna Pharmaceuticals (dicerna.com).
Websites whose visitors overlap most with Dicerna Pharmaceuticals. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| cerecor.com | 100% | View details | |||
| avanir.com | 92% | View details | |||
marinabio.com | marinabio.com | 92% | – | ||
| concertpharma.com | 92% | View details | |||
| sirnaomics.com | 91% | 1.9K | #8,322,653 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 6 similar websites and full traffic analytics for Dicerna Pharmaceuticals
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 6 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Dicerna Pharmaceuticals (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dicerna Pharmaceuticals
Complete news archive for Dicerna Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dicerna Pharmaceuticals
Dicerna Pharmaceuticals was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Dicerna Pharmaceuticals is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Dicerna Pharmaceuticals is a funded company, having raised a total of $106.45M across 7 funding rounds to date. The company's 1st funding round was a Series A of $8.4M, raised on Jul 2008.
Dicerna Pharmaceuticals has 337 employees.
Annual revenue of Dicerna Pharmaceuticals is $164.31M as on Dec 31, 2020.
Founded in 2007, Dicerna Pharmaceuticals is based in Lexington, United States, within the biotechnology sector. Therapeutics are developed through RNA interference technology for various conditions. A lead RNA product targets hepatocellular carcinoma, while other candidates address primary hyperoxaluria, genetic liver diseases, cardiovascular issues, and hepatitis B virus. The GalXC platform is applied to silence genes associated with these diseases.
Dicerna Pharmaceuticals's top competitors include Alnylam, Avidity Biosciences and Denali Therapeutics.
Dicerna Pharmaceuticals offers Wegovy and Ozempic.
Dicerna Pharmaceuticals has 17 investors. Key investors include Lilly, Novo Nordisk, RA Capital, Bain Capital Private Equity, and Abingworth.
Dicerna Pharmaceuticals operates through Dicerna Pharmaceuticals Inc.
Yes. Dicerna Pharmaceuticals was acquired by Novo Nordisk in November 2021.